Publication

This paper argues that in pharmaceutical markets, variation in the arrival time of consumer heterogeneity creates differences between a producer’s ability to extract consumer surplus with preventives and treatments, potentially distorting R&D decisions. For example, the authors' research shows that the US distribution of HIV risk would lead firms to earn only half the revenue from a vaccine as from a drug. This means that preventative vaccines are less likely to be developed for such diseases.